Terms ending in 2039

Cellectis

Every in-force patent on Cellectis's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.

Patent	Title	Holder	Status	Expires	Confidence
US 12,152,081	Chimeric Antigen Receptors Targeting CD70 Pfizer Inc. In force Term ends Feb 20, 2039 · Medium confidence	Pfizer Inc.	In force	Term ends Feb 20, 2039	Medium confidence
US 12,012,607	Engineering Wheat with Increased Dietary Fiber Cellectis In force Term ends Jul 3, 2039 · High confidence	Cellectis	In force	Term ends Jul 3, 2039	High confidence
US 11,396,551	Chimeric Antigen Receptors Targeting CD70 Pfizer Inc. In force Term ends Jul 9, 2039 · Medium confidence	Pfizer Inc.	In force	Term ends Jul 9, 2039	Medium confidence
US 11,624,072	Canola with High Oleic Acid Cellectis In force Term ends Jul 9, 2039 · High confidence	Cellectis	In force	Term ends Jul 9, 2039	High confidence
US 11,873,511	Targeted Gene Insertion for Improved Immune Cells Therapy Cellectis In force Term ends Sep 1, 2039 · High confidence	Cellectis	In force	Term ends Sep 1, 2039	High confidence
US 11,690,873	New Universal Chimeric Antigen Receptor T Cells Specific for CD22 Cellectis S.A. In force Term ends Nov 3, 2039 · High confidence	Cellectis S.A.	In force	Term ends Nov 3, 2039	High confidence
US 11,944,643	Universal ANTI-CD22 Chimeric Antigen Receptor Engineered Immune Cells Cellectis S.A. In force Term ends Nov 3, 2039 · High confidence	Cellectis S.A.	In force	Term ends Nov 3, 2039	High confidence

7 of 7 patents shown. Soonest term end first, then patent number.

5 of these are in force and held by Cellectis.

Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.